WO2003055916A3 - Adiponectin fragments and conjugates - Google Patents

Adiponectin fragments and conjugates Download PDF

Info

Publication number
WO2003055916A3
WO2003055916A3 PCT/DK2002/000897 DK0200897W WO03055916A3 WO 2003055916 A3 WO2003055916 A3 WO 2003055916A3 DK 0200897 W DK0200897 W DK 0200897W WO 03055916 A3 WO03055916 A3 WO 03055916A3
Authority
WO
WIPO (PCT)
Prior art keywords
adiponectin
polypeptide
amino acid
acid residue
conjugate
Prior art date
Application number
PCT/DK2002/000897
Other languages
French (fr)
Other versions
WO2003055916A2 (en
Inventor
Poul Baad Rasmussen
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Torben Halkier
Are Bogsnes
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Poul Baad Rasmussen
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Torben Halkier
Are Bogsnes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps, Maxygen Holdings Ltd, Poul Baad Rasmussen, Kim Vilbour Andersen, Anders Hjelholt Pedersen, Hans Thalsgaard Schambye, Torben Halkier, Are Bogsnes filed Critical Maxygen Aps
Priority to AU2002358467A priority Critical patent/AU2002358467A1/en
Priority to CA002468619A priority patent/CA2468619A1/en
Priority to EP02792711A priority patent/EP1458758A2/en
Priority to US10/498,665 priority patent/US20060052292A1/en
Priority to JP2003556446A priority patent/JP2005526492A/en
Publication of WO2003055916A2 publication Critical patent/WO2003055916A2/en
Publication of WO2003055916A3 publication Critical patent/WO2003055916A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue. The non-polypeptide moiety may be a polymer, e.g. PEG. Further described is an isolated complex comprising an adiponectin trimer and calcium ions. The conjugate or complex is used in the treatment of disorders such as type 2 diabetes, cardiovascular disease and septic shock.
PCT/DK2002/000897 2001-12-21 2002-12-20 Adiponectin fragments and conjugates WO2003055916A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002358467A AU2002358467A1 (en) 2001-12-21 2002-12-20 Adiponectin fragments and conjugates
CA002468619A CA2468619A1 (en) 2001-12-21 2002-12-20 Adiponectin fragments and conjugates
EP02792711A EP1458758A2 (en) 2001-12-21 2002-12-20 Adiponectin fragments and conjugates
US10/498,665 US20060052292A1 (en) 2001-12-21 2002-12-20 Adiponectin fragments and conjugates
JP2003556446A JP2005526492A (en) 2001-12-21 2002-12-20 Adiponectin fragments and conjugates

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US34348201P 2001-12-21 2001-12-21
US60/343,482 2001-12-21
DKPA200101952 2001-12-21
DKPA200101952 2001-12-21
US37549202P 2002-04-25 2002-04-25
DKPA200200627 2002-04-25
US60/375,492 2002-04-25
DKPA200200627 2002-04-25
US39411702P 2002-07-03 2002-07-03
DKPA200201036 2002-07-03
DKPA200201036 2002-07-03
US60/394,117 2002-07-03
US41216902P 2002-09-20 2002-09-20
US60/412,169 2002-09-20
DKPA200201385 2002-09-20
DKPA200201385 2002-09-20

Publications (2)

Publication Number Publication Date
WO2003055916A2 WO2003055916A2 (en) 2003-07-10
WO2003055916A3 true WO2003055916A3 (en) 2003-12-31

Family

ID=27570813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000897 WO2003055916A2 (en) 2001-12-21 2002-12-20 Adiponectin fragments and conjugates

Country Status (5)

Country Link
EP (1) EP1458758A2 (en)
JP (1) JP2005526492A (en)
AU (1) AU2002358467A1 (en)
CA (1) CA2468619A1 (en)
WO (1) WO2003055916A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534699A (en) 2002-01-18 2008-12-24 Protemix Corp Ltd Glycoisoforms of adiponectin and uses thereof
EP1506229A1 (en) * 2002-05-17 2005-02-16 Serono Genetics Institute S.A. Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders
ATE478890T1 (en) * 2002-05-31 2010-09-15 Serono Genetics Inst Sa HOMOTRIMERIC EXTENDED GLOBULAR HEAD OF OBG3 AND USES THEREOF
US7176292B2 (en) * 2003-09-11 2007-02-13 Dialean, Ltd. Ghrelin variant protein
EP2279745B1 (en) * 2004-03-31 2012-02-08 Kazuhisa Maeda Adiponectin as endotoxin-neutralising agent
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
JP2008526885A (en) * 2005-01-07 2008-07-24 ゼンコア Adiponectin mutant
US7749956B2 (en) 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7592423B2 (en) 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
WO2006104964A2 (en) * 2005-03-28 2006-10-05 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30
CN1740195B (en) * 2005-04-15 2012-01-04 复旦大学 Polypeptide gapM1 and its prepn process
WO2007008937A2 (en) * 2005-07-11 2007-01-18 Xencor Adiponectin variants
US7709607B2 (en) 2005-07-11 2010-05-04 Xencor, Inc. Adiponectin variants
US20090291091A1 (en) * 2005-07-29 2009-11-26 Laboratoires Serono Sa Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
CA2636724A1 (en) 2006-01-09 2007-08-02 Children's Hospital Medical Center Adiponectin for treatment of various disorders
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
US8026345B2 (en) * 2007-01-08 2011-09-27 Hoffmann-La Roche Inc. Characterization and identification of unique human adiponectin isoforms and antibodies
CN103228290A (en) 2011-02-18 2013-07-31 (株)斯坦帝尔 Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
CN104004066B (en) * 2013-02-26 2017-05-31 上海市第一人民医院 Prevention suppresses inflammatory reaction and micromolecule polypeptide and its application of angiogenesis
WO2018004067A1 (en) * 2016-07-01 2018-01-04 전남대학교 산학협력단 Adiponectin overexpression cell line
CN112209995B (en) * 2020-10-14 2022-01-11 华兰基因工程有限公司 Preparation method of SARS-CoV-2 surface protein receptor binding region
CN112521481B (en) * 2020-12-08 2022-11-04 武汉市工程科学技术研究院 Surface modifier and preparation method and application thereof
CN112574306B (en) * 2020-12-17 2023-05-05 武汉华美生物工程有限公司 Adiponectin monoclonal antibody, antibody pair, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0152847A1 (en) * 1984-02-03 1985-08-28 Abbott Laboratories Stabilized enzyme conjugate composition
WO2001051645A1 (en) * 2000-01-14 2001-07-19 Genset Obg3 globular head and uses thereof for decreasing body mass

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0152847A1 (en) * 1984-02-03 1985-08-28 Abbott Laboratories Stabilized enzyme conjugate composition
WO2001051645A1 (en) * 2000-01-14 2001-07-19 Genset Obg3 globular head and uses thereof for decreasing body mass

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BERG A H ET AL: "The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.", NATURE MEDICINE. UNITED STATES AUG 2001, vol. 7, no. 8, August 2001 (2001-08-01), pages 947 - 953, XP002242789, ISSN: 1078-8956 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988, FORMANOWSKI F ET AL: "ISOLATION OF THE INFLUENZA C VIRUS GLYCOPROTEIN IN A SOLUBLE FORM BY BROMELAIN DIGESTION", XP002255332, Database accession no. PREV198886054594 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, LANZA F ET AL: "DIFFERENTIAL EFFECTS OF EXTRA AND INTRACELLULAR CALCIUM CHELATION ON HUMAN PLATELET FUNCTION AND GLYCOPROTEIN IIB-IIIA COMPLEX STABILITY", XP002255334, Database accession no. PREV199294001032 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, CASTON JOSE R ET AL: "S-layer protein from Thermus thermophilus HB8 assembles into porin-like structures.", XP002255333, Database accession no. PREV199396092136 *
FRUEBIS J ET AL: "Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 13 FEB 2001, vol. 98, no. 4, 13 February 2001 (2001-02-13), pages 2005 - 2010, XP002242791, ISSN: 0027-8424 *
MOLECULAR MICROBIOLOGY, vol. 9, no. 1, 1993, pages 65 - 75, ISSN: 0950-382X *
NOUVELLE REVUE FRANCAISE D'HEMATOLOGIE, vol. 34, no. 1, 1992, pages 123 - 131, ISSN: 0029-4810 *
SHAPIRO L ET AL: "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor.", CURRENT BIOLOGY: CB. ENGLAND 12 MAR 1998, vol. 8, no. 6, 12 March 1998 (1998-03-12), pages 335 - 338, XP002242793, ISSN: 0960-9822 *
VIRUS RESEARCH, vol. 10, no. 2-3, 1988, pages 177 - 192, ISSN: 0168-1702 *
WANG YU ET AL: "Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 31 MAY 2002, vol. 277, no. 22, 31 May 2002 (2002-05-31), pages 19521 - 19529, XP002242790, ISSN: 0021-9258, Retrieved from the Internet <URL:http://www.jbc.org/cgi/content/full/277/22/19521> [retrieved on 20030528] *
YAMAUCHI T ET AL: "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.", NATURE MEDICINE. UNITED STATES AUG 2001, vol. 7, no. 8, August 2001 (2001-08-01), pages 941 - 946, XP002242792, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
CA2468619A1 (en) 2003-07-10
EP1458758A2 (en) 2004-09-22
WO2003055916A2 (en) 2003-07-10
JP2005526492A (en) 2005-09-08
AU2002358467A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2003055916A3 (en) Adiponectin fragments and conjugates
YU48703A (en) New interferon beta-like molecules
WO2005055950A3 (en) Glycopegylated factor ix
WO2006116475A3 (en) Immunostimulatory compositions
WO2006031811A3 (en) Glycopegylated interferon alpha
WO2006127896A3 (en) Glycopegylated factor ix
WO2001079464A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
HK1051964A1 (en) G-csf conjugates g-csf
WO2005051327A3 (en) Glycopegylated erythropoietin
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
WO2001058935A3 (en) FACTOR VII OR VIIa-LIKE MOLECULES
WO2003008444A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
WO2002032461A3 (en) Protein c or activated protein c-like molecules
WO2001015736A3 (en) Interferon-beta conjugates
WO2002040037A3 (en) M. tuberculosis chaperonin 60.1 and uses thereof
WO2002036614A3 (en) Peptides for use in the treatment of alzheimer&#39;s disease
WO2001010408A3 (en) Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
WO2001042474A3 (en) Interferon-like molecules and uses thereof
AU2002309122A1 (en) Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes
WO2004074454A3 (en) Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
EP2275118A3 (en) Pancreas-specific proteins
CA2205771A1 (en) Improved delivery of disease modifiers
WO2003025014A3 (en) Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2468619

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003556446

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002792711

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1579/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002358467

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002792711

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006052292

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10498665

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10498665

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002792711

Country of ref document: EP